TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0120nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.110nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.120nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.410nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 160nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
